vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
BIOMERICA INC is the larger business by last-quarter revenue ($1.2M vs $908.9K, roughly 1.3× T Stamp Inc). BIOMERICA INC runs the higher net margin — -109.1% vs -279.9%, a 170.8% gap on every dollar of revenue. On growth, BIOMERICA INC posted the faster year-over-year revenue change (-26.0% vs -39.3%). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -12.1%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
BMRA vs IDAI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $908.9K |
| Net Profit | $-1.3M | $-2.5M |
| Gross Margin | 4.2% | — |
| Operating Margin | -113.5% | -224.9% |
| Net Margin | -109.1% | -279.9% |
| Revenue YoY | -26.0% | -39.3% |
| Net Profit YoY | -38.9% | 57.7% |
| EPS (diluted) | $-0.45 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $908.9K | ||
| Q3 25 | $1.4M | $872.5K | ||
| Q2 25 | — | $812.7K | ||
| Q1 25 | $1.1M | $545.5K | ||
| Q4 24 | $1.6M | $1.5M | ||
| Q3 24 | $1.8M | $511.1K | ||
| Q2 24 | $1.1M | $500.4K | ||
| Q1 24 | $1.0M | $573.7K |
| Q4 25 | $-1.3M | $-2.5M | ||
| Q3 25 | $2.0K | $-1.9M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | $-1.2M | $-2.2M | ||
| Q4 24 | $-950.0K | $-6.0M | ||
| Q3 24 | $-1.3M | $-1.3M | ||
| Q2 24 | $-1.4M | $-2.6M | ||
| Q1 24 | $-1.9M | $-2.7M |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -113.5% | -224.9% | ||
| Q3 25 | -81.0% | -203.0% | ||
| Q2 25 | — | -207.0% | ||
| Q1 25 | -108.1% | -396.5% | ||
| Q4 24 | -60.7% | -81.2% | ||
| Q3 24 | -75.7% | -523.7% | ||
| Q2 24 | -136.6% | -524.7% | ||
| Q1 24 | -196.7% | -496.7% |
| Q4 25 | -109.1% | -279.9% | ||
| Q3 25 | 0.1% | -219.1% | ||
| Q2 25 | — | -210.7% | ||
| Q1 25 | -103.9% | -395.5% | ||
| Q4 24 | -58.1% | -401.5% | ||
| Q3 24 | -72.8% | -245.7% | ||
| Q2 24 | -127.1% | -519.3% | ||
| Q1 24 | -188.6% | -466.9% |
| Q4 25 | $-0.45 | $-0.37 | ||
| Q3 25 | $0.00 | $-0.72 | ||
| Q2 25 | — | $-0.69 | ||
| Q1 25 | $-0.48 | $-0.89 | ||
| Q4 24 | $-0.06 | $-3.14 | ||
| Q3 24 | $-0.63 | $-1.06 | ||
| Q2 24 | $-2.57 | $-3.19 | ||
| Q1 24 | $-0.11 | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4M | $8.7M |
| Total Assets | $6.0M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | $6.0M | ||
| Q3 25 | $3.1M | $5.4M | ||
| Q2 25 | — | $292.1K | ||
| Q1 25 | $3.1M | $1.1M | ||
| Q4 24 | $2.4M | $2.8M | ||
| Q3 24 | $2.8M | $598.0K | ||
| Q2 24 | $4.2M | $659.5K | ||
| Q1 24 | $5.3M | $816.7K |
| Q4 25 | $4.4M | $8.7M | ||
| Q3 25 | $5.2M | $6.1M | ||
| Q2 25 | — | $2.4M | ||
| Q1 25 | $5.5M | $4.1M | ||
| Q4 24 | $5.1M | $3.0M | ||
| Q3 24 | $5.3M | $5.4M | ||
| Q2 24 | $6.6M | $750.4K | ||
| Q1 24 | $7.8M | $1.4M |
| Q4 25 | $6.0M | $11.2M | ||
| Q3 25 | $6.9M | $11.2M | ||
| Q2 25 | — | $5.7M | ||
| Q1 25 | $7.4M | $6.6M | ||
| Q4 24 | $7.3M | $8.6M | ||
| Q3 24 | $7.9M | $10.6M | ||
| Q2 24 | $9.3M | $5.2M | ||
| Q1 24 | $10.3M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $2.0M |
| Free Cash FlowOCF − Capex | — | $2.0M |
| FCF MarginFCF / Revenue | — | 215.4% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | $2.0M | ||
| Q3 25 | $-268.0K | $-4.0M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | $-1.0M | $-1.5M | ||
| Q4 24 | $-791.0K | $-2.7M | ||
| Q3 24 | $-1.3M | $-2.4M | ||
| Q2 24 | $-1.0M | $-1.6M | ||
| Q1 24 | $-1.8M | $-2.2M |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $-2.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-1.1M | $-1.6M | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | — | 215.4% | ||
| Q3 25 | — | -459.6% | ||
| Q2 25 | — | -258.6% | ||
| Q1 25 | — | -289.2% | ||
| Q4 24 | — | -182.9% | ||
| Q3 24 | — | -475.4% | ||
| Q2 24 | -95.5% | -320.9% | ||
| Q1 24 | — | -376.6% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | 2.1% | 1.3% | ||
| Q1 24 | 0.0% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
